表紙
市場調查報告書

膀胱癌:流行病學的預測 (到2028年)

Bladder Cancer: Epidemiology Forecast to 2028

出版商 GlobalData 商品編碼 928974
出版日期 內容資訊 英文 49 Pages
訂單完成後即時交付
價格
膀胱癌:流行病學的預測 (到2028年) Bladder Cancer: Epidemiology Forecast to 2028
出版日期: 2020年02月28日內容資訊: 英文 49 Pages
簡介

全球主要7個國家的膀胱癌的發病數量,預計2018∼2028年之間從22萬5000件到27萬5000件,以年度平均 (AGR) 2.21%的速度增加。隨之,預計醫療費的財政負擔額 (市場規模) 也增大。

本報告提供全球主要7個國家 (美國、法國、德國、義大利、西班牙、英國、日本) 的膀胱癌的發病情形與今後預測相關分析,疾病的特徵和目前患病者的發病情形,今後10年的患病數量的預測值等調查。

第1章 目錄

第2章 膀胱癌:摘要整理

第3章 流行病學

  • 疾病的背景
  • 風險要素
  • 全球市場的過去趨勢
    • 主要國家 (7MM)的已受診發病者數的趨勢
  • 預測手法
    • 資訊來源
    • 預測的前提條件與手法
  • 膀胱癌的流行病學的預測 (2018∼2028年)
    • 膀胱癌已診斷的發病者數
    • 膀胱癌已診斷的發病者數:各年齡
    • 膀胱癌已診斷的發病者數:男女
    • 膀胱癌已診斷的5年患病人數
    • 膀胱癌已診斷的發病者數:受診時的各病期
    • 膀胱癌已診斷的發病者數:階段Ta的情況 (各等級)
    • 膀胱癌已診斷的發病者數:各腫瘤的發生處
    • 膀胱癌已診斷的發病者數:第4階段轉移的情況 (各狀況)
    • 膀胱癌已診斷的發病者數:伴隨FGFR3突然變異的情況 (各類型)
    • 膀胱癌已診斷的發病者數 (階段T2/T3/T4):伴隨PD-L1表現的情況
    • 膀胱癌已診斷的發病者數:伴隨HER-2過剩表現的情況
    • 膀胱癌已診斷的發病者數:治療後2年的復發數量
  • 討論
    • 流行病學的預測相關考察
    • 分析的限制
    • 分析的優勢

第4章 附錄

目錄
Product Code: GDHCER230-20

The financial burden of diagnosed bladder cancer is expected to grow between 2018 and 2028 in the seven major markets (The US, France, Germany, Italy, Spain, the UK and Japan) due to an increase in disease incident cases from over 225,000 to 275,000, at an annual growth rate (AGR) of 2.21.

Bladder cancer is a common cancer worldwide that occurs when there is uncontrolled cell growth in the bladder lining, most commonly in urothelial cells. The most common risk factor of bladder cancer is tobacco use and cigarette smoking. The risk of bladder cancer also increases with older age, with people ages 65 years and older accounting for 70% of cases. Men are also four times more likely to develop bladder cancer compared with women. Bladder cancer types include carcinoma in situ (CIS), a flat tumor in the inner layer of the bladder that is also referred to as stage Tis.

However, smoking rates have decreased in the 7MM (The US, France, Germany, Italy, Spain, the UK), including in Japan. A more convincing reason for the increase of cases is that the risk of developing bladder cancer increases with age. In the 7MM (The US, France, Germany, Italy, Spain, the UK and Japan) combined, the highest proportion of diagnosed incident cases of bladder cancer in 2018 was among the 70-79 years age group.

The US had the highest number of diagnosed incident and diagnosed prevalent cases of bladder cancer. In 2018, the US had over 76,000 diagnosed incident cases of bladder cancer and the number is expected to increase to more than 96,000 diagnosed incident cases by 2028 at an AGR of 2.58%. The increase in diagnosed incident cases may be due to changes in population and to steadily increasing incidence of bladder cancer in specific age groups. Japan will see the largest increase of cases through the forecast period, at an AGR of 2.99%.

The latest report "Bladder Cancer: Epidemiology Forecast to 2028" provides an overview of the risk factors and global trends of bladder cancer in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).

The report also includes a 10-year epidemiological forecast for the following segmentations in all ages across the 7MM: diagnosed incident cases of bladder cancer; five-year diagnosed prevalent cases of bladder cancer; diagnosed incident cases of bladder cancer by stage at diagnosis (Ta, Tis, T1, T2, T3, and T4), stage Ta grade, tumor location, stage T4 metastasis, and mutations and biomarkers; and two-year recurrence of diagnosed incident cases of bladder cancer.

Scope

  • Bladder Cancer Epidemiology Report provides an overview of the risk factors and global trends of bladder cancer in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
  • This report also includes a 10-year epidemiological forecast for the following segmentations in all ages across the 7MM: diagnosed incident cases of bladder cancer; five-year diagnosed prevalent cases of bladder cancer; diagnosed incident cases of bladder cancer by stage at diagnosis (Ta, Tis, T1, T2, T3, and T4), stage Ta grade, tumor location, stage T4 metastasis, and mutations and biomarkers; and two-year recurrence of diagnosed incident cases of bladder cancer.
  • The Bladder Cancer Epidemiology Report is written and developed by Masters- and PhD-level epidemiologists.
  • The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

The Bladder Cancer Epidemiology series will allow you to -

  • Develop business strategies by understanding the trends shaping and driving the global bladder cancer market.
  • Quantify patient populations in the global bladder cancer market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups that present the best opportunities for bladder cancer therapeutics in each of the markets covered.
  • Understand magnitude bladder cancer market by stage, mutations and biomarkers.

Table of Contents

1 Table of Contents

  • 1.1 List of Tables
  • 1.2 List of Figures

2 Bladder Cancer: Executive Summary

  • 2.1 Catalysts
  • 2.2 Related Reports
  • 2.3 Upcoming Reports

3 Epidemiology

  • 3.1 Disease Background
  • 3.2 Risk Factors
  • 3.3 Global and Historical Trends
    • 3.3.1 7MM Trends in Diagnosed Incidence
  • 3.4 Forecast Methodology
    • 3.4.1 Sources
    • 3.4.2 Forecast Assumptions and Methods
  • 3.5 Epidemiological Forecast for Bladder Cancer (2018-2028)
    • 3.5.1 Diagnosed Incident Cases of Bladder Cancer
    • 3.5.2 Age-Specific Diagnosed Incident Cases of Bladder Cancer
    • 3.5.3 Sex-Specific Diagnosed Incident Cases of Bladder Cancer
    • 3.5.4 Five-Year Diagnosed Prevalent Cases of Bladder Cancer
    • 3.5.5 Diagnosed Incident Cases of Bladder Cancer by Stage at Diagnosis
    • 3.5.6 Diagnosed Incident Cases of Bladder Cancer by Stage Ta by Grade
    • 3.5.7 Diagnosed Incident Cases of Bladder Cancer by Tumor Location
    • 3.5.8 Diagnosed Incident Cases of Bladder Cancer by Stage T4 Metastasis
    • 3.5.9 Diagnosed Incident Cases of Bladder Cancer with FGFR3 Mutations
    • 3.5.10 Diagnosed Incident Cases of Bladder Cancer (Stages T2, T3, and T4) with PD-L1 Expression
    • 3.5.11 Diagnosed Incident Cases of Bladder Cancer with HER-2 Overexpression
    • 3.5.12 Two-Year Recurrence of Diagnosed Incident Cases of Bladder Cancer
  • 3.6 Discussion
    • 3.6.1 Epidemiological Forecast Insight
    • 3.6.2 Limitations of Analysis
    • 3.6.3 Strengths of Analysis

4 Appendix

  • 4.1 Bibliography
  • 4.2 About the Authors
    • 4.2.1 Epidemiologist
    • 4.2.2 Reviewers
    • 4.2.3 Global Director of Therapy Analysis and Epidemiology
    • 4.2.4 Global Head and EVP of Healthcare Operations and Strategy
  • 4.3 About GlobalData
  • 4.4 Contact Us
  • 4.5 Disclaimer

List of Tables

  • Table 1: Summary of Newly Added Data Types and Countries
  • Table 2: Summary of Updated Data Types
  • Table 3: Risk Factors for Bladder Cancer
  • Table 4: 7MM, Two-Year Recurrence of Diagnosed Incident Cases of Bladder Cancer, Both Sexes, Ages ≥18 Y

List of Figures

  • Figure 1: 7MM, Diagnosed Incident Cases of Bladder Cancer, Both Sexes, Ages ≥18 Years, 2018 and 2028, N
  • Figure 2: 7MM, Diagnosed Prevalent Cases of Bladder Cancer, Both Sexes, Ages ≥18 Years, 2018 and 2028, N
  • Figure 3: 7MM, Diagnosed Incidence of Bladder Cancer, Men, Ages ≥18 Years, 2008-2028, Cases per 100,000 Population
  • Figure 4: 7MM, Diagnosed Incidence of Bladder Cancer, Women, Ages ≥18 Years, 2008-2028, Cases per 100,000 Population
  • Figure 5: Sources Used and Not Used for Diagnosed Incident Cases of Bladder Cancer
  • Figure 6: Sources Used for Diagnosed Incident Cases of Bladder Cancer by Stage at Diagnosis
  • Figure 7: Sources Used for Diagnosed Incident Cases of Bladder Cancer Stage Ta by Grade
  • Figure 8: Sources Used for Diagnosed Incident Cases of Bladder Cancer Stage by Tumor Location
  • Figure 9: Sources Used for Diagnosed Incident Cases of Bladder Cancer Stage T4 by Metastasis
  • Figure 10: Sources Used for Five-Year Diagnosed Prevalent Cases of Bladder Cancer
  • Figure 11: Sources Used for Diagnosed Incident Cases of Bladder Cancer by Mutations and Biomarkers
  • Figure 12: Sources Used for Two-Year Recurrence of Diagnosed Incident Cases of Bladder Cancer
  • Figure 13: 7MM, Diagnosed Incident Cases of Bladder Cancer, Both Sexes, Ages ≥18 Years, 2018
  • Figure 14: 7MM, Age-Specific Diagnosed Incident Cases of Bladder Cancer, Both Sexes, Ages ≥18 Years, 2018, N
  • Figure 15: 7MM, Sex-Specific Diagnosed Incident Cases of Bladder Cancer, Both Sexes, Ages ≥18 Years, 2018, N
  • Figure 16: 7MM, Five-Year Diagnosed Prevalent Cases of Bladder Cancer, Both Sexes, Ages ≥18 Years, 2018
  • Figure 17: 7MM, Diagnosed Incident Cases of Bladder Cancer by Stage at Diagnosis, Both Sexes, Ages ≥18 Years, 2018, N
  • Figure 18: 7MM, Diagnosed Incident Cases of Bladder Cancer Stage Ta by Grade, Both Sexes, Ages ≥18 Years, 2018, N
  • Figure 19: 7MM, Diagnosed Incident Cases of Bladder Cancer by Tumor Location, Both Sexes, Ages ≥18 Years, 2018, N
  • Figure 20: 7MM, Diagnosed Incident Cases of Bladder Cancer by Stage T4 Metastasis, Both Sexes, Ages ≥18 Years, 2018, N
  • Figure 21: 7MM, Diagnosed Incident Cases of Bladder Cancer with FGFR3 Mutations, Both Sexes, Ages ≥18 Years, 2018, N
  • Figure 22: 7MM, Diagnosed Incident Cases of Bladder Cancer (Stages T2, T3, and T4) with PD-L1 Expression, Both Sexes, Ages ≥18 Years, 2018, N
  • Figure 23: 7MM, Diagnosed Incident Cases of Bladder Cancer with HER-2 Overexpression, Both Sexes, Ages ≥18 Years, 2018, N